dc.contributor.author | Anzala, Aggrey O. | |
dc.contributor.author | Jaoko Walter G. | |
dc.contributor.author | Karita, E. | |
dc.contributor.author | Kayitenkore, K. | |
dc.contributor.author | Than, S. | |
dc.contributor.author | Adams, EM. | |
dc.contributor.author | Graham, BS. | |
dc.contributor.author | Koup, RA. | |
dc.contributor.author | Bailer, RT. | |
dc.contributor.author | Smith, C. | |
dc.contributor.author | Dally, L. | |
dc.contributor.author | Farah, B. | |
dc.contributor.author | Muvunyi, CM. | |
dc.contributor.author | Bizimana, J. | |
dc.contributor.author | Tarragona-Fiol, T. | |
dc.contributor.author | Bergin, PJ. | |
dc.contributor.author | Hayes, P. | |
dc.contributor.author | Ho, M. | |
dc.contributor.author | Loughran, K. | |
dc.contributor.author | Komaroff, W. | |
dc.contributor.author | Stevens, G. | |
dc.contributor.author | Thomson, H. | |
dc.contributor.author | Boaz, MJ. | |
dc.contributor.author | Cox, JH. | |
dc.contributor.author | Schmidt, C. | |
dc.contributor.author | Gilmour, J. | |
dc.contributor.author | Nabel, GJ. | |
dc.contributor.author | Fast, P. | |
dc.date.accessioned | 2013-06-29T07:46:20Z | |
dc.date.available | 2013-06-29T07:46:20Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | Jaoko, W., KKO-MATAEMGBSKRABEKG, RT., Smith DFANZALAMCMBT-FBPJHHCLB, M., Loughran KSTBMJCJHSGNGJFKWG. 2010. Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa. PLoS ONE . 5(9) | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/20877623 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/42119 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943475/ | |
dc.description.abstract | Abstract
BACKGROUND:
We conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env from subtypes A, B and C, given alone or as boost following a DNA plasmid vaccine expressing the same HIV-1 proteins plus Nef, in 114 healthy HIV-uninfected African adults.
METHODOLOGY/PRINCIPAL FINDINGS:
Volunteers were randomized to 4 groups receiving the rAd5 vaccine intramuscularly at dosage levels of 1×10(10) or 1×10(11) particle units (PU) either alone or as boost following 3 injections of the DNA vaccine given at 4 mg/dose intramuscularly by needle-free injection using Biojector® 2000. Safety and immunogenicity were evaluated for 12 months. Both vaccines were well-tolerated. Overall, 62% and 86% of vaccine recipients in the rAd5 alone and DNA prime - rAd5 boost groups, respectively, responded to the HIV-1 proteins by an interferon-gamma (IFN-γ) ELISPOT. The frequency of immune responses was independent of rAd5 dosage levels. The highest frequency of responses after rAd5 alone was detected at 6 weeks; after DNA prime - rAd5 boost, at 6 months (end of study). At baseline, neutralizing antibodies against Ad5 were present in 81% of volunteers; the distribution was similar across the 4 groups. Pre-existing immunity to Ad5 did not appear to have a significant impact on reactogenicity or immune response rates to HIV antigens by IFN-γ ELISPOT. Binding antibodies against Env were detected in up to 100% recipients of DNA prime - rAd5 boost. One volunteer acquired HIV infection after the study ended, two years after receipt of rAd5 alone.
CONCLUSIONS/SIGNIFICANCE:
The HIV-1 rAd5 vaccine, either alone or as a boost following HIV-1 DNA vaccine, was well-tolerated and immunogenic in African adults. DNA priming increased the frequency and magnitude of cellular and humoral immune responses, but there was no effect of rAd5 dosage on immunogenicity endpoints. | |
dc.language.iso | en | en |
dc.publisher | University of nairobi | en |
dc.title | Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa | en |
dc.type | Article | en |
local.publisher | College of health science | en |